These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15565603)

  • 1. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Kronenberger B; Herrmann E; Micol F; von Wagner M; Zeuzem S
    Hepatology; 2004 Dec; 40(6):1442-9. PubMed ID: 15565603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Puoti C; Bellis L; Castellacci R; Montagnese F
    Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
    Hiramatsu N; Inoue Y; Oze T; Kurashige N; Yakushijin T; Mochizuki K; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Hayashi N
    J Gastroenterol; 2011 Nov; 46(11):1335-43. PubMed ID: 21858637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
    Coban S; Idilman R; Erden E; Tüzün A
    Hepatogastroenterology; 2011; 58(109):1301-6. PubMed ID: 21937399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
    Zeuzem S; Diago M; Gane E; Reddy KR; Pockros P; Prati D; Shiffman M; Farci P; Gitlin N; O'Brien CB; Lamour F; Lardelli P;
    Gastroenterology; 2004 Dec; 127(6):1724-32. PubMed ID: 15578510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.
    Hsu CS; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
    Intervirology; 2007; 50(4):310-5. PubMed ID: 17622791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Bini EJ; Mehandru S
    Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
    Puoti C; Pellicelli AM; Romano M; Mecenate F; Guarisco R; Barbarini G; Mazzoni E; Spilabotti L; Bellis L; Paglia F; Barlattani A; Picardi A; Paffetti A; Bonaventura ME; Nosotti L; Mitidieri O; Dell'Unto O; Villani R; Dell'Unto C; Morrone A; Soccorsi F;
    Liver Int; 2009 Nov; 29(10):1479-84. PubMed ID: 19422478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
    J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.
    Gordon SC; Fang JW; Silverman AL; McHutchison JG; Albrecht JK
    Hepatology; 2000 Aug; 32(2):400-4. PubMed ID: 10915749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
    Kowala-Piaskowska A; Figlerowicz M; Mozer-Lisewska I; Słuzewski W
    Przegl Epidemiol; 2005; 59(2):491-8. PubMed ID: 16190558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.
    Hui CK; Monto A; Belaye T; Lau E; Wright TL
    Gut; 2003 Nov; 52(11):1644-8. PubMed ID: 14570736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Pawłowska M; Palewicz E; Halota W
    Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.